A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
about
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsNew ways to successfully target tumor vasculature in ovarian cancer.Current status of bevacizumab in advanced ovarian cancerOxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.Emerging therapies: angiogenesis inhibitors for ovarian cancer.Oxaliplatin for the treatment of ovarian cancer.
P2860
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@en
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@nl
type
label
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@en
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@nl
prefLabel
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@en
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@nl
P2093
P2860
P921
P1433
P1476
A phase II trial of oxaliplati ...... eritoneum, and fallopian tube.
@en
P2093
Barrett H Childs
Bradley J Monk
Jeffrey F Hines
Lynda D Roman
Maria C Bell
Mark H Einstein
Patricia Braly
Peter G Rose
Richard D Drake
Robert M Wenham
P2860
P304
P356
10.1016/J.YGYNO.2014.01.035
P407
P577
2014-01-27T00:00:00Z